Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Total Current Liabilities (2018 - 2025)

Abvc Biopharma (ABVC) has disclosed Total Current Liabilities for 12 consecutive years, with $6.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Current Liabilities fell 6.0% year-over-year to $6.2 million, compared with a TTM value of $6.2 million through Dec 2025, down 6.0%, and an annual FY2025 reading of $6.2 million, down 6.0% over the prior year.
  • Total Current Liabilities was $6.2 million for Q4 2025 at Abvc Biopharma, down from $6.5 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $6.7 million in Q1 2025 and bottomed at $3.4 million in Q3 2021.
  • Average Total Current Liabilities over 5 years is $5.3 million, with a median of $5.7 million recorded in 2022.
  • The sharpest move saw Total Current Liabilities plummeted 43.12% in 2021, then surged 58.34% in 2023.
  • Year by year, Total Current Liabilities stood at $3.7 million in 2021, then surged by 50.14% to $5.5 million in 2022, then rose by 10.07% to $6.1 million in 2023, then rose by 7.47% to $6.6 million in 2024, then decreased by 6.0% to $6.2 million in 2025.
  • Business Quant data shows Total Current Liabilities for ABVC at $6.2 million in Q4 2025, $6.5 million in Q3 2025, and $6.5 million in Q2 2025.